Securities code: Berry Genomics Co.Ltd(000710) securities abbreviation: Berry Genomics Co.Ltd(000710) Announcement No.: 2022018 Berry Genomics Co.Ltd(000710)
Summary of annual report 2021
1、 Important note: the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should carefully read the full text of the annual report in the media designated by the CSRC. In addition to the following directors, other directors attended the meeting of the board of directors to consider the annual report in person
Name of director not present in person position of director not present in person reason for not attending the meeting name of the entrusted person
Tips on non-standard audit opinions □ applicable √ not applicable to the profit distribution plan of ordinary shares or the plan of converting accumulation fund into share capital in the reporting period considered by the board of directors □ applicable √ not applicable. The company plans not to distribute cash dividends, bonus shares or convert accumulation fund into share capital. Preferred stock profit distribution plan for the reporting period adopted by the board of directors □ applicable √ not applicable II. Basic information of the company 1. Company profile
Stock abbreviation Berry Genomics Co.Ltd(000710) Stock Code: Berry Genomics Co.Ltd(000710)
Shenzhen Stock Exchange
Contact person and contact information secretary of the board of directors securities affairs representative
Name: AI Wenlu Dong Yuhuan
Office address: Building 5, courtyard 4, shengshengyuan Road, Science Park, Changping District, Beijing Building 5, courtyard 4, shengshengyuan Road, Science Park, Changping District, Beijing
Fax 0108430682401084306824
Tel: 0105325918801053259188
E-mail Berry Genomics Co.Ltd(000710) @berrygenomics.com. Berry Genomics Co.Ltd(000710) @berrygenomics.com.
2. Main business or product introduction during the reporting period (I) the main business of the company is gene testing services and sales of equipment and reagents based on high-throughput sequencing technology. Focusing on “medical products and services”, the company has formed a business system focusing on the application of “Genetics” and continuously expanding to the field of “big data”. Specific products and services are as follows: 1. Medical products and services 1) genetics
The company mainly provides reproductive health and genetic disease gene testing products and services covering the tertiary prevention of birth defects: the primary prevention field mainly carries out carrier screening gene testing before and during pregnancy, including spinal muscular atrophy (SMA) gene testing, fragile X syndrome carrier screening (FXS), folate metabolism gene testing, genetic deafness gene testing, etc, At the same time, carry out “Ke yun’an” preimplantation genetic test (PGT) in the field of assisted reproduction; In the field of secondary prevention, we mainly carry out “bebian” noninvasive prenatal gene testing (NIPT) for chromosome aneuploidy screening and “bebian plus” noninvasive prenatal testing (NIPT plus) for 100 chromosome diseases and genomic diseases screening. At the same time, we also carry out “konoan” chromosome copy number variation detection (CNV SEQ) in the field of prenatal diagnosis and abortion genetics etiology detection; In the field of tertiary prevention, we mainly carry out whole exome sequencing (WES) and whole genome sequencing (WGS). Relying on the third-generation sequencing technology, the company carries out “screening for carriers of thalassemia” (third-generation thalassemia). The third-generation thalassemia has irreplaceable advantages in improving the prevention and control efficiency of severe thalassemia, avoiding unnecessary prenatal diagnosis caused by misscreening and clinical accurate genetic counseling. List of main products of genetic application:
Name test item application field sample test content
Noninvasive prenatal gene detection of 13, 18 and 21 fetal chromosomal aneuploidy in peripheral blood of reproductive healthy pregnant women
（NIPT）
Bebian plus noninvasive prenatal gene detection 17 fetal chromosome aneuploidies including 13, 18, 21 and sex chromosome aneuploidy (NIPT pus) in the peripheral blood of reproductive healthy pregnant women 76 kinds of fetal chromosome large fragment microdeletion and microcoincidence syndrome greater than 10MB and 7 kinds of relatively high incidence of microdeletion diseases located at the location of chromosome fragments related to specific syndrome
Konoan chromosome copy number variation detection reproductive health, amniotic fluid, umbilical cord blood, one-time analysis of 23 pairs of chromosome aneuploidy and 100 (CNV SEQ) transmission detection of abortion, peripheral KB chromosome copy number variation (CNVs)
Blood, etc
Keyun’an preimplantation genetics test reproductive health blastomere single-cell chromosome aneuploidy, microdeletion microdeletion (PGT) greater than 10MB or blastocyst trophoblast coincidence and unbalanced translocation
Cells
The safe exon group of Beiquan is used to detect reproductive health, peripheral blood and abortion exons (the collection of Wes transmission detection tissues and DNA in all exon regions of the genome), which is conducive to the detection of gene variation and improve the diagnosis rate of genetic diseases. It is applied to ophthalmology, cardiovascular system Neurological diseases, endocrinology, metabolism, orthopedics, respiration, kidney, blood, immunity, digestion, skin and pediatrics
Using the third-generation sequencing technology to promote reproductive health and peripheral blood, the third-generation poverty can cover more than 30 kinds at one time α There are more than 28 kinds of screening diseases in thalassemia carriers β Missing variation, exceeding all previous methods of poverty detection; Can accurately detect α Gene multi copy variation, help α Multi copy merge β Precise prevention and control of “class III” land poverty with genetic variation; Be able to accurately identify Hong Kong type and anti Hong Kong type variants to avoid misscreening; It can realize the accurate identification of CIS and trans variants in place at one time, without family verification, and reduce the back and forth of pregnant women and their families.
For the rare type of thalassemia whose cause cannot be determined by conventional gene detection methods, the third generation of thalassemia can improve the diagnostic efficiency by 40-60%; For the false positive and false negative of traditional PCR and second-generation thalassemia, it can also be verified by third-generation thalassemia
Screening the copy number of exon 7 of SMN1 gene and the number of CGG repeats in the regulatory region of FMR1 gene in reproductive healthy peripheral blood of SMA and FXS carriers with propranolol
Detection of nine hot spot genes in reproductive healthy peripheral blood (GJB2, SLC26A4 (PDS)
Gjb3, 12S rRNA, KCNQ4, Coch, pou3f4, GJB6, tmie)
Detection of folate metabolic capacity gene of Berean: C677T and A1298C sites of 5,10-methylenetetrahydrofolate reductase (MTHFR) gene and A66G site of methionine synthase reductase (MTRR) in reproductive healthy peripheral blood
2) Reagent sales gene sequencing requires the use of reagent groups such as DNA extraction reagent, DNA purification reagent, library building reagent and sequencing reagent. NIPT database building reagent of the company applies the self-developed ez-palo rapid database building method, which can easily and quickly complete the database building. The main reagent products of the company are shown in the table below:
Product name product number specification registration / filing number reagent type technical advantages
Nextseq cn500 r0075 1 test / packaging, 75 cycle Zhejiang Hangzhou Machinery General sequencing reagent, sequencing high-throughput sequencing Kit / testing cooperated with Illumina, high-throughput 20150116 reagent, its performance is equivalent to r0150 1 test / packaging, 150 cycle Zhejiang Hangzhou Machinery General sequencing reagent Illumina, with stable, quasi ring / testing, Characteristics of high flux 20150116
R0300 1 test / packaging, 300 general sequencing reagent prepared by Zhejiang Hangzhou Machinery
Ring / test, high flux 20150116
Nextseq cn500 r0151 1 test / packaging, 150 loop / testing of sequencing medium flux sequencing kit prepared by Zhejiang Hangzhou Machinery Co., Ltd. and Illumina, zhongflux 20150249 reagent, its performance is equivalent to R0301 1 1 test / packaging, 300 loop / testing of Zhejiang Hangzhou Machinery Co., Ltd. and medium flux 20
